An AI-designed universal coronavirus vaccine just passed its first human test

Quietly, over the past month, a genuine first happened in AI-assisted medicine: a vaccine whose active component was designed entirely by computer simulation has now been tested in humans and shown safe. Cambridge researchers and spinout DIOSynVax reported that their needle-free DNA vaccine, pEVAC-PS, completed Phase I trials in 39 healthy volunteers with no significant side effects, per the university’s research announcement, with results published in the Journal of Infection. This is not breaking news by the clock, the trial data emerged in early June, but it has resurfaced in wider discussion this week, and it has not had the attention the milestone deserves.

What the AI actually designed

The vaccine targets sarbecoviruses broadly, the family that includes SARS-CoV-2 and its bat-virus relatives, rather than one strain. Researchers used AI to analyze genetic sequence data across the family and design a “super-antigen”: a synthetic protein built from the conserved structural features that do not mutate away, rather than the fast-changing spike regions current vaccines target. That is the specific, checkable claim, and it holds up: the design step, not the manufacturing or delivery, is where the AI contribution lives.

Why a physician reads this as a genuine first, cautiously

Phase I answers exactly one question: is it safe. It does not yet answer whether the vaccine actually prevents infection or disease in a real outbreak, that requires Phase II and III data against a real pathogen challenge, which does not yet exist for this candidate. The AI-drug-discovery caution I raised in our explainer on how the field actually works applies directly here: this is design speed and safety, not proof of efficacy. What makes it worth covering now is the concept, an AI-designed antigen built for mutation resistance rather than chasing the current variant, is a genuinely different approach from how flu and COVID vaccines have historically been updated.

What to watch

Watch for Phase II trial registration and timeline, whether the pan-sarbecovirus approach gets licensed or replicated by larger vaccine manufacturers, and whether this becomes a template other AI-vaccine-design efforts point to as proof of concept.